What is the share price of Vista Pharmaceuticals Ltd (VISTAPH) today?
The share price of VISTAPH as on 18th July 2025 is ₹11.10. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Vista Pharmaceuticals Ltd (VISTAPH) share?
The past returns of Vista Pharmaceuticals Ltd (VISTAPH) share are- Past 1 week: -0.70%
- Past 1 month: 6.49%
- Past 3 months: -0.44%
- Past 6 months: 5.24%
- Past 1 year: -23.73%
- Past 3 years: 60.71%
- Past 5 years: 5.53%
What are the peers or stocks similar to Vista Pharmaceuticals Ltd (VISTAPH)?
The peers or stocks similar to Vista Pharmaceuticals Ltd (VISTAPH) include:What is the market cap of Vista Pharmaceuticals Ltd (VISTAPH) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Vista Pharmaceuticals Ltd (VISTAPH) is ₹69.68 Cr as of 18th July 2025.What is the 52 week high and low of Vista Pharmaceuticals Ltd (VISTAPH) share?
The 52-week high of Vista Pharmaceuticals Ltd (VISTAPH) is ₹15.70 and the 52-week low is ₹9.10.What is the PE and PB ratio of Vista Pharmaceuticals Ltd (VISTAPH) stock?
The P/E (price-to-earnings) ratio of Vista Pharmaceuticals Ltd (VISTAPH) is -15.02. The P/B (price-to-book) ratio is 1.72.Which sector does Vista Pharmaceuticals Ltd (VISTAPH) belong to?
Vista Pharmaceuticals Ltd (VISTAPH) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Vista Pharmaceuticals Ltd (VISTAPH) shares?
You can directly buy Vista Pharmaceuticals Ltd (VISTAPH) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Vista Pharmaceuticals Ltd
VISTAPH Share Price
11.101.94% (-0.22)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
VISTAPH Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
LowProfitability and efficiency haven't been upto the mark
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
VISTAPH Performance & Key Metrics
VISTAPH Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -15.05 | 1.72 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 37.28 | 6.66 | 0.80% |
VISTAPH Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
VISTAPH Company Profile
Vista Pharmaceuticals is engaged in manufacturing and selling of pharmaceutical, medical and veterinary preparations
SUNPHARMA
PE Ratio
37.40
37.40
1Y Return
6.23%
6.23%
Buy Reco %
84.85
84.85
CIPLA
PE Ratio
22.71
22.71
1Y Return
1.62%
1.62%
Buy Reco %
68.75
68.75
TORNTPHARM
PE Ratio
62.06
62.06
1Y Return
15.14%
15.14%
Buy Reco %
70.83
70.83
MANKIND
PE Ratio
54.71
54.71
1Y Return
24.01%
24.01%
Buy Reco %
81.25
81.25
DRREDDY
PE Ratio
18.59
18.59
1Y Return
5.70%
5.70%
Buy Reco %
48.39
48.39
VISTAPH Forecast
VISTAPH Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
VISTAPH
VISTAPH
Income
Balance Sheet
Cash Flow
Annual Normal View
VISTAPH Income Statement
VISTAPH Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 24.24 | 29.32 | 34.02 | 26.51 | 1.47 | 0.56 | 1.40 | 10.62 | 10.52 | 10.52 | ||||||||||
Raw Materials | 20.68 | 14.75 | 26.81 | 22.90 | 0.73 | 0.37 | 2.83 | 8.88 | 14.10 | 14.10 | ||||||||||
| Power & Fuel Cost | 0.50 | 0.70 | 0.46 | 0.39 | 0.28 | 0.22 | 0.23 | 0.57 | ||||||||||||
| Employee Cost | 0.70 | 0.87 | 1.18 | 1.31 | 1.15 | 0.57 | 0.51 | 1.79 | ||||||||||||
| Selling & Administrative Expenses | 2.46 | 2.63 | 1.18 | 1.12 | 0.60 | 0.37 | 0.51 | 1.26 | ||||||||||||
| Operating & Other expenses | -3.22 | 4.62 | 0.20 | 1.84 | 0.24 | 0.14 | 1.24 | 1.34 | ||||||||||||
EBITDA | 3.12 | 5.75 | 4.19 | -1.05 | -1.53 | -1.11 | -3.92 | -3.22 | -3.58 | -3.58 | ||||||||||
| Depreciation/Amortization | 1.02 | 1.34 | 1.36 | 1.35 | 0.73 | 0.62 | 0.62 | 0.72 | 0.74 | 0.73 | ||||||||||
| PBIT | 2.10 | 4.41 | 2.83 | -2.40 | -2.26 | -1.73 | -4.54 | -3.94 | -4.32 | -4.31 | ||||||||||
| Interest & Other Items | 0.88 | 1.57 | 1.67 | 1.54 | 1.55 | 0.90 | 1.34 | 1.24 | 0.96 | 0.96 | ||||||||||
| PBT | 1.22 | 2.84 | 1.16 | -3.94 | -3.81 | -2.63 | -5.88 | -5.18 | -5.28 | -5.27 | ||||||||||
| Taxes & Other Items | -0.02 | 0.64 | 0.21 | -0.26 | -1.80 | -1.73 | -0.21 | -0.67 | -0.64 | -0.64 | ||||||||||
| Net Income | 1.24 | 2.20 | 0.95 | -3.68 | -2.01 | -0.90 | -5.67 | -4.51 | -4.64 | -4.63 | ||||||||||
| EPS | 0.48 | 0.79 | 0.32 | -1.21 | -0.60 | -0.24 | -1.53 | -1.06 | -0.79 | -0.98 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
VISTAPH Company Updates
VISTAPH Stock Peers
VISTAPH Past Performance & Peer Comparison
VISTAPH Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Vista Pharmaceuticals Ltd | -15.02 | 1.72 | — |
| Sun Pharmaceutical Industries Ltd | 37.40 | 5.64 | 0.94% |
| Cipla Ltd | 22.71 | 3.83 | 1.08% |
| Torrent Pharmaceuticals Ltd | 62.06 | 15.63 | 0.91% |
VISTAPH Stock Price Comparison
Compare VISTAPH with any stock or ETFCompare VISTAPH with any stock or ETF
VISTAPH
VISTAPH Holdings
VISTAPH Shareholdings
VISTAPH Promoter Holdings Trend
VISTAPH Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
VISTAPH Institutional Holdings Trend
VISTAPH Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
VISTAPH Shareholding Pattern
VISTAPH Shareholding Pattern
VISTAPH Shareholding History
VISTAPH Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing VISTAPH stock
smallcases containing VISTAPH stock
Looks like this stock is not in any smallcase yet.
VISTAPH Events
VISTAPH Events
VISTAPH Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
VISTAPH has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
VISTAPH Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
VISTAPH has not given any dividends in last 5 years
VISTAPH Dividends
VISTAPH Dividends
Hmm, looks like data is unavailable here. Please come back after some timeVISTAPH Stock News & Opinions
VISTAPH Stock News & Opinions
Articles & Videos
Earnings
Vista Pharmaceuticals reports standalone net loss of Rs 1.50 crore in the March 2025 quarter
Net loss of Vista Pharmaceuticals reported to Rs 1.50 crore in the quarter ended March 2025 as against net profit of Rs 0.09 crore during the previous quarter ended March 2024. Sales rose 3.19% to Rs 3.23 crore in the quarter ended March 2025 as against Rs 3.13 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 4.65 crore in the year ended March 2025 as against net loss of Rs 4.51 crore during the previous year ended March 2024. Sales declined 2.14% to Rs 10.07 crore in the year ended March 2025 as against Rs 10.29 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales3.233.13 3 10.0710.29 -2 OPM %-28.488.31 --40.02-34.69 - PBDT-0.890.08 PL -4.55-4.46 -2 PBT-1.07-0.10 -970 -5.29-5.18 -2 NP-1.500.09 PL -4.65-4.51 -3 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Vista Pharmaceuticals to discuss results
Vista Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 30 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Vista Pharmaceuticals schedules EGM
Vista Pharmaceuticals announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 20 March 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Vista Pharmaceuticals to convene board meeting
Vista Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 19 February 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Vista Pharmaceuticals reports standalone net loss of Rs 1.32 crore in the December 2024 quarter
Net Loss of Vista Pharmaceuticals reported to Rs 1.32 crore in the quarter ended December 2024 as against net loss of Rs 1.63 crore during the previous quarter ended December 2023. Sales rose 50.59% to Rs 2.56 crore in the quarter ended December 2024 as against Rs 1.70 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales2.561.70 51 OPM %-58.98-102.35 - PBDT-1.61-2.02 20 PBT-1.80-2.20 18 NP-1.32-1.63 19 Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Vista Pharmaceuticals to table results
Vista Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 February 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Vista Pharmaceuticals reports standalone net loss of Rs 0.97 crore in the September 2024 quarter
Net Loss of Vista Pharmaceuticals reported to Rs 0.97 crore in the quarter ended September 2024 as against net loss of Rs 2.02 crore during the previous quarter ended September 2023. Sales declined 28.24% to Rs 2.49 crore in the quarter ended September 2024 as against Rs 3.47 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales2.493.47 -28 OPM %-33.33-33.72 - PBDT-1.07-1.41 24 PBT-1.25-1.59 21 NP-0.97-2.02 52 Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Vista Pharmaceuticals to convene board meeting
Vista Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Vista Pharmaceuticals to conduct AGM
Vista Pharmaceuticals announced that the 33th Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live
10 months agoCapital Market - Live
Earnings
Vista Pharmaceuticals reports standalone net loss of Rs 0.86 crore in the June 2024 quarter
Net Loss of Vista Pharmaceuticals reported to Rs 0.86 crore in the quarter ended June 2024 as against net loss of Rs 0.95 crore during the previous quarter ended June 2023. Sales declined 9.09% to Rs 1.80 crore in the quarter ended June 2024 as against Rs 1.98 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales1.801.98 -9 OPM %-43.33-45.96 - PBDT-0.99-1.11 11 PBT-1.17-1.28 9 NP-0.86-0.95 9 Powered by Capital Market - Live
11 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of -16.88%, vs industry avg of 10.45%
Over the last 5 years, market share decreased from 0.01% to 0%